Dynavax (DVAX) Tops Q3 EPS by 14c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
November 2, 2023 4:01 PM EDTGenerated quarterly HEPLISAV-B® vaccine net product revenue of $62.3 million, a 66% year-over-year increaseRaising full year HEPLISAV-B net product revenue guidance to $210 - $220 million, compared to prior range of $200 - $215 millionCash and investments increased to $720 million at quarter end; expects positive free cash flow for full yearConference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., Nov. 2, 2023 /PRNewswire/... More
